Third Generation Antifungal Drugs of the Echinocandin Class to Overcome Resistance in Invasive Candidiasis
|
Third-Generation Echinocandins: Re-engineering the Gold Standard of Antifungal Therapy to Defeat Drug Resistance
Modality: Drug |
|
A novel class of resistance-breaking antifungal drugs, designed to remain effective against multidrug-resistant Candida including Candida auris and Candida glabrata.
The Challenge
Every year, invasive Candida infections kill nearly one million people worldwide. For critically ill patients, echinocandins are the frontline treatment and the most important class of antifungal drugs available.
However, resistance is rising rapidly, particularly in Candida auris - one of the World Health Organization's highest-priority fungal threats. The newest echinocandin, rezafungin, solved major dosing and stability limitations through convenient once-weekly administration, yet remains vulnerable to the same resistance mechanisms threatening the entire class.
Our Breakthrough
We have developed what may represent the next evolutionary step in antifungal therapy: Third-Generation Echinocandins. Using a practical two-step synthetic transformation, we created entirely new chemical entities that restore activity against echinocandin-resistant fungal strains while preserving the favorable properties of current therapies.
- Restore activity against echinocandin-resistant fungi
- Preserve long-acting profile
- Improve stability and membrane interactions
- Maintain activity against clinically important echinocandin-resistant Candida species
- Offer a realistic path toward scalable manufacturing
Key Proof Points
- Novel chemical entities (NCEs)
- Gram-scale synthesis established
- Effective against echinocandin-resistant Candida auris and Candida glabrata
- Patent application in preparation
Market Opportunity
The global echinocandin market exceeds $1 billion annually and continues to grow as antifungal resistance rises. Resistance-breaking echinocandin could become the next standard of care for invasive candidiasis, hospital-acquired fungal infections, and treatment of vulnerable immunocompromised patients.
Our Vision
To develop the world’s first Third-Generation Echinocandin, a resistance-breaking antifungal that combines the safety and durable activity against multidrug-resistant Candida. Better chemistry. Better antifungals. Better clinical outcomes.
Related researches >>
Related videos >>
Gallery >>
Back to Infectious Diseases Research lobby >>
Explore
